Immune Activation in Patients with Locally Advanced Cervical Cancer Treated with Ipilimumab Following Definitive Chemoradiation (GOG-9929).

Diane M Da SilvaDanielle M EnserroJyoti S MayadevJoseph G SkeateKoji MatsuoHuyen Q PhamHeather A LankesKatherine M MoxleySharad A GhamandeYvonne G LinRussell J SchilderMichael J BirrerW Martin Kast

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)

Our data indicate that CRT alone and combined with ipilimumab immunotherapy show immune-modulating activity in women with locally advanced cervical cancer and may be a promising therapeutic option for the enhancement of antitumor immune cell function after primary CRT for this population at high risk for recurrence and metastasis. Several key immune biomarkers were identified that were associated with clinical response.

Keyphrases

locally advanced
rectal cancer
neoadjuvant chemotherapy
squamous cell carcinoma
radiation therapy
phase ii study
heart failure
big data
signaling pathway
clinical trial
artificial intelligence
data analysis
study protocol
newly diagnosed
open label
placebo controlled